ObjectiveTo comparatively analyze the clinical effect and safety of metformin sustained-release tablets and metformin immediate-release tablets in the treatment of patients with newly diagnosed type 2 diabetes mellitus (T2DM). MethodsA total of 98 newly diagnosed T2DM patients admitted to our hospital between March 2019 and June 2020 were selected as the research objects and were divided into sustained-release group and immediate-release group by the random number method, with 49 cases in each group. Patients in the sustained-release group were treated with metformin sustained-release tablets, whereas patients in the immediate-release group were treated with metformin immediate-release tablets. After continuous treatment for 3 months, the clinical efficacy of the two groups was compared. The changes in blood glucose, blood lipid and intestinal floras were compared between the two groups before and after treatment. The occurrence of adverse reactions during treatment was also compared between the two groups. ResultsAfter 3 months of treatment, there was no statistically significant difference in the total effective rate of treatment between the two groups (P＞0.05). Before treatment, fasting blood glucose (FBG) and 2h postprandial blood glucose (2hPBG), total cholesterol (TC) and triglyceride (TG) levels were not significantly different between the two groups (P＞0.05). After 3 months of treatment, the levels of FBG, 2hPBG, TC and TG in both groups significantly decreased (P＜0.05), but there were no statistically significant differences in FBG, 2hPBG, TC and TG between the two groups (P＞0.05). Before treatment, there were no statistically significant differences in the number of intestinal bifidobacterium, lactobacilus and bacteroide between the two groups (P＞0.05). After 3 months of treatment, the number of intestinal bifidobacterium, lactobacillus and bacteroide in both groups significantly increased (P＜0.05), but there were no statistically significant differences in the number of intestinal bifidobacterium, lactobacilus and bacteroide between the two groups (P＞0.05). During treatment, the occurrence of adverse reactions in the sustained-release group (8.16%) was significantly higher than that in the immediate-release group (22.45%), with a statistically significant difference between the two groups (P＜0.05). ConclusionBoth sustained-release and immediate-release tablets of metformin can effectively decrease blood glucose and blood lipid levels and regulate intestinal flora of patients with T2MD, with similar clinical efficacy; however, there are fewer side effects and more convenient to use in patients treated with metformin sustained-release tablets.

无